- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: AT-527 is the hemi-sulfate salt prodrug of AT-511, which is a direct-acting antiviral compound that disrupts activity of the viral RNA polymerase . It was originally developed to combat hepatitis C (HCV) infection, but has been redeployed for SARS-CoV-2. Chemically AT-527 is a phosphoramidate purine nucleotide and it is metabolised to a biologically active guanosine triphosphate analogue in vivo. Preclinical results showing pan-genotype activity against HCV were published in early 2020 . As of October 2020 anti-SARS-CoV-2 activity has been disclosed in preprint format .
AT-527 was developed by Atea Pharmaceuticals. In October 2020 it was announced that Roche were purchasing the rights to AT-527 outside of the US. In the same press release, it was revealed that AT-527 would be entering Phase 3 trial in early 2021 to evaluate its efficacy as an early treatment for COVID-19 in non-hospitalised patients.
|Compound class||Synthetic organic|
|GtoPdb PubChem SID||434321730|
|Search Google for chemical match using the InChIKey||OISLSHLAXHALQZ-ZXWZJMKMSA-N|
|Search Google for chemicals with the same backbone||OISLSHLAXHALQZ|
|Search UniChem for chemical match using the InChIKey||OISLSHLAXHALQZ-ZXWZJMKMSA-N|
|Search UniChem for chemicals with the same backbone||OISLSHLAXHALQZ|